It contains 97.0%~102.0% of Sacubitril and Valsartan (C48H55N6O8), calculated on anhydrous, solvent-free and free acid basis.

共有 1 個藥物證書使用此成份

琥醯聯苯壓利-纈戊醯洒坦
Sacubitril and Valsartan

• 申請商: 西海生技股份有限公司
• 適應症: 治療慢性心臟衰竭
• 發證日期: 2023-09-07